OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Michael Peel

1 Projects | 1 Researchers | $523,940 Invested

2016

Cypralis Ltd

Michael Peel, PhD

Selective Cyclophilin D inhibitors for neurodegeneration

  • Funding Amount: $523,940
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Mitochondria/Metabolic Function
  • Status: Closed